Last Update: Aug 25, 2023
Purchase the complete database including drugs in pre-clinical development (30+ rows), discontinued programs and quarterly US and ex-US sales of Lumakras/Lumykras.
| Company | Product | MOA | Indications | Approval |
|---|---|---|---|---|
| Amgen | LUMAKRAS/LUMYKRAS (sotorasib) | KRAS G12C inhibitor | KRAS G12C-mutated locally advanced or metastatic NSCLC | 05/21 (US) 01/22 (EU) |
| Mirati Therapeutics | KRAZATI (adagrasib) | KRAS G12C inhibitor | 2L KRAS G12C-mutated locally advanced or metastatic NSCLC | 12/22 (US) |
| Company | Candidate | MOA | Indications | Phase |
|---|---|---|---|---|
| Amgen | Sotorasib (AMG 510) | KRAS G12C inhibitor | KRAS G12C-mutant NSCLC, advanced CRC, pancreatic and other solid tumors | III |
| Mirati | Adagrasib (MRTX849) | KRAS G12C inhibitor | KRAS G12C-mutant NSCLC, CRC, pancreatic | III |
| Novartis | JDQ443 | KRAS G12C inhibitor | KRAS G12C-mutant solid tumors (±TNO155 & spartalizumab) | III |
| Inventisbio/Chia-Tai Tianqing | D-1553 | KRAS G12C inhibitor | KRAS G12C-mutant NSCLC, CRC, other tumors (monotherapy+combination) | II |
| Genentech (Roche) | Divarasib (GDC-6036) | KRAS G12C inhibitor | KRAS G12C-mutant NSCLC, CRC, advanced solid tumors | Ib/II |
| Moderna | mRNA-5671 | KRAS vaccine | NSCLC, CRC, advanced solid tumors | I |
| Revolution Medicines | RMC-6236 | Multi-RAS(ON) (H-,K-,N-) inhibitor | KRAS-mutant advanced solid tumors | I/Ib |
| Jacobio Pharma | JAB-21822 | KRAS G12C inhibitor | KRAS G12C-mutant NSCLC, CRC, advanced solid tumors | I/II |
| Innovent Biologics | IBI351 (GFH925) | KRAS G12C inhibitor | KRAS G12C-mutant NSCLC, CRC, advanced solid tumors | I |
| Eli Lilly | LY3537982 | KRAS G12C inhibitor | KRAS G12C-mutant advanced solid tumors | Ia/Ib |
| Elicio Therapeutics | ELI-002 | KRAS vaccine with AMP | KRAS-mutated PDAC and other solid tumors | I |
| Alaunos Therapeutics | TCR-T Library | Neoantigen-specific TCR T cell (KRAS G12D) | KRAS-mutant solid tumors | I |
| Astellas Pharma | ASP3082 | KRAS G12D PROTAC | KRAS G12D mutant solid tumors | I |
| Revolution Medicines | RMC-6291 | K/NRAS G12C (ON) | KRAS G12C-mutant cancers | I/Ib |
| Immuneering | IMM-1-104 | Dual MEK 1/2 inhibitor/pan-KRAS/NRAS | RAS-mutant advanced or metastatic solid tumors | I/IIa |
| Erasca | ERAS-3490 | KRAS G12C inhibitor | KRAS G12C-mutant solid tumors | I |
| Company | Candidate | MOA | Indications | Phase |
|---|---|---|---|---|
| Boehringer (Lupin) | BI 1701963 | SOS1 inhibitor | KRAS-mutant cancer w/ Adagrasib or MEK inhibitor (Trametinib) | I/Ib |
| Mirati | MRTX0902 | SOS1 inhibitor | Combination with KRAS inhibitor (adagrasib) | I/II |
| Company | Candidate | MOA | Indications | Phase |
|---|---|---|---|---|
| Revolution Medicines | RMC-4630 | SHP2 inhibitor | RTK cancers (+-MEKi, +- sotorasib, +- LY3214996 +- pembrolizumab, +-adagrasib) | Ib/II |
| Novartis | TNO155 | SHP2 inhibitor | KRAS-mutant cancers (combination trials), BRAF V600 CRC, Hepatic impairment | I/II |
| Bristol Myers Squibb & BridgeBio | BBP-398 | SHP2 inhibitor | RTK cancers (KRAS-mutant NSCLC +nivolumab or +sotorasib), EGFRm advanced solid tumors | Ib |
| Relay Therapeutics & Genentech | RLY-1971 (GDC-1971) | SHP2 inhibitor | RTK cancers (advanced or metastatic solid tumors +- atezolizumab +- GDC-6036) | Ib |
| Pfizer | PF-07284892 (ARRY-558) | SHP2 inhibitor | RTK cancers (BRAF V600E, RASm, ALK+) +- encorafenib, +- cetuximab | I |
| AbbVie | JAB-3312 | SHP2 inhibitor | RTK cancers +- MEKi, +- anti-PD1, +- KRAS G12Ci (JAB-21822) | I/IIa |
| Erasca | ERAS-601 | SHP2 inhibitor | RAS/MAPK-altered advanced or metastatic solid tumors (+- cetuximab +- ERAS-007 +- sotorasib) | I/II |
| HUYA bioscience | HBI-2376 | SHP2 inhibitor | KRAS/EGFR-mutant advanced or metastatic solid tumors | I |
| Nanjing Sanhome | SH3809 | SHP2 inhibitor | Advanced solid tumors | I |
| Etern Therapeutics | ET0038 | SHP2 inhibitor | Advanced solid tumors (+pembrolizumab) | I |
| Betta Pharmaceuticals (Xcovery) | BPI-442096 | SHP2 inhibitor | Advanced solid tumors (NSCLC, CRC, pancreatic) | I |